Table 2.
Open in new tab

Baseline disease characteristics in the efficacy cohort.

n = 33
Presence of extra-intestinal manifestations14 [42%]
History of IBD surgery25 [76%]
Laboratory parameters, median [IQR]
 Faecal calprotectin, µg/g [n = 12]598.0 [190.0, 1531.3]
 hs-CRP, mg/L [n = 24]11.0 [2.0, 37.3]
 ESR, mm/h [n = 14]23.5 [9.0, 51.0]
 Haemoglobin, g/dL [n = 28]12.7 [11.4, 13.5]
Prior thiopurine or methotrexate use33 [97%]
Prior biologics use
 Prior TNF antagonist use33 [100%]
  One agent2 [6.1%]
  Two agents13 [39.4%]
  Three of more agents18 [54.5%]
 Prior vedolizumab use33 [100%]
 Prior ustekinumab use33 [100%]
Prior dual biologic or biologic/small molecule use5 [15.2%]
Prior tofacitinib use5 [15.2%]
Baseline corticosteroid use with upadacitinib19 [57.6%]
Baseline median SES-CD score [n = 13]15 [10, 26]
Follow-up timea, days, median [IQR]243 [174, 363.5]
n = 33
Presence of extra-intestinal manifestations14 [42%]
History of IBD surgery25 [76%]
Laboratory parameters, median [IQR]
 Faecal calprotectin, µg/g [n = 12]598.0 [190.0, 1531.3]
 hs-CRP, mg/L [n = 24]11.0 [2.0, 37.3]
 ESR, mm/h [n = 14]23.5 [9.0, 51.0]
 Haemoglobin, g/dL [n = 28]12.7 [11.4, 13.5]
Prior thiopurine or methotrexate use33 [97%]
Prior biologics use
 Prior TNF antagonist use33 [100%]
  One agent2 [6.1%]
  Two agents13 [39.4%]
  Three of more agents18 [54.5%]
 Prior vedolizumab use33 [100%]
 Prior ustekinumab use33 [100%]
Prior dual biologic or biologic/small molecule use5 [15.2%]
Prior tofacitinib use5 [15.2%]
Baseline corticosteroid use with upadacitinib19 [57.6%]
Baseline median SES-CD score [n = 13]15 [10, 26]
Follow-up timea, days, median [IQR]243 [174, 363.5]

aPatients were followed until upadacitinib was discontinued.

IBD, inflammatory bowel disease; IQR, interquartile range; SD, standard deviation; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; TNF, tumour necrosis factor; SES-CD, Simple Endoscopic Score for Crohn’s Disease.

Table 2.
Open in new tab

Baseline disease characteristics in the efficacy cohort.

n = 33
Presence of extra-intestinal manifestations14 [42%]
History of IBD surgery25 [76%]
Laboratory parameters, median [IQR]
 Faecal calprotectin, µg/g [n = 12]598.0 [190.0, 1531.3]
 hs-CRP, mg/L [n = 24]11.0 [2.0, 37.3]
 ESR, mm/h [n = 14]23.5 [9.0, 51.0]
 Haemoglobin, g/dL [n = 28]12.7 [11.4, 13.5]
Prior thiopurine or methotrexate use33 [97%]
Prior biologics use
 Prior TNF antagonist use33 [100%]
  One agent2 [6.1%]
  Two agents13 [39.4%]
  Three of more agents18 [54.5%]
 Prior vedolizumab use33 [100%]
 Prior ustekinumab use33 [100%]
Prior dual biologic or biologic/small molecule use5 [15.2%]
Prior tofacitinib use5 [15.2%]
Baseline corticosteroid use with upadacitinib19 [57.6%]
Baseline median SES-CD score [n = 13]15 [10, 26]
Follow-up timea, days, median [IQR]243 [174, 363.5]
n = 33
Presence of extra-intestinal manifestations14 [42%]
History of IBD surgery25 [76%]
Laboratory parameters, median [IQR]
 Faecal calprotectin, µg/g [n = 12]598.0 [190.0, 1531.3]
 hs-CRP, mg/L [n = 24]11.0 [2.0, 37.3]
 ESR, mm/h [n = 14]23.5 [9.0, 51.0]
 Haemoglobin, g/dL [n = 28]12.7 [11.4, 13.5]
Prior thiopurine or methotrexate use33 [97%]
Prior biologics use
 Prior TNF antagonist use33 [100%]
  One agent2 [6.1%]
  Two agents13 [39.4%]
  Three of more agents18 [54.5%]
 Prior vedolizumab use33 [100%]
 Prior ustekinumab use33 [100%]
Prior dual biologic or biologic/small molecule use5 [15.2%]
Prior tofacitinib use5 [15.2%]
Baseline corticosteroid use with upadacitinib19 [57.6%]
Baseline median SES-CD score [n = 13]15 [10, 26]
Follow-up timea, days, median [IQR]243 [174, 363.5]

aPatients were followed until upadacitinib was discontinued.

IBD, inflammatory bowel disease; IQR, interquartile range; SD, standard deviation; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; TNF, tumour necrosis factor; SES-CD, Simple Endoscopic Score for Crohn’s Disease.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close